Cogent Biosciences is focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Lead program, bezuclastinib, is being developed for Systemic Mastocytosis and Gastrointestinal Stromal Tumors. In addition, the Research Team is developing a portfolio of novel therapies initially targeting FGFR2 and ErbB2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com